Bace1 inhibitory antibodies
AssigneesVib Vzw, Katholieke Universiteit Leuven, K.U.Leuven R&D
InventorsBart De Strooper, Lujia Zhou, Wim Annaert
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
Claims18
An isolated anti-BACE antibody that is able to inhibit BACE1's activity.
An active fragment of an antibody wherein said active fragment is able to inhibit BACE1's activity.
A hybridoma cell line with accession number LMBP 6871CB or LMBP 6872CB or LMBP 6873CB.
(canceled)
A method of producing an antibody able to inhibit BACE1 activity, the method comprising the steps of:
- (i) immunizing a non-human animal with BACE1;
- and
- (ii) screening a plurality of hybridoma lines for an antibody able to inhibit BACE1 activity.
A monoclonal antibody produced by a hybridoma cell line selected from the group of consisting of:
- Accession Number LMBP 6871CB as deposited under the provisions of the Budapest Treaty with the Belgian Co-ordinated Collections of Micro-organisms, Zwijnaarde, Belgium, on May 13, 2009,
- Accession Number LMBP 6872CB as deposited under the provisions of the Budapest Treaty with the Belgian Co-ordinated Collections of Micro-organisms, Zwijnaarde, Belgium, on May 13, 2009, and
- Accession Number LMBP 6873CB as deposited under the provisions of the Budapest Treaty with the Belgian Co-ordinated Collections of Micro-organisms, Zwijnaarde, Belgium, on May 13, 2009.
Dependencies are inferred from the claim text.